Exact Sciences Completes Acquisition of Ashion Analytics, LLC, from The Translational Genomics Research Institute, an affiliate of City of Hope
Talented team and industry-leading lab will help strengthen the company's sequencing and pipeline capabilities, while broadening its therapy selection and treatment guidance offerings
News provided by
Share this article
(PRNewsfoto/EXACT SCIENCES CORP)
(PRNewsfoto/EXACT SCIENCES CORP)
MADISON, Wis., April 14, 2021 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced that it has completed its previously announced acquisition of Ashion Analytics, LLC.
"As a leader in cancer testing, we're committed to providing earlier answers and life-changing treatment guidance to support patients along every step of their cancer journey," said Kevin Conroy, chairman and CEO of Exact Sciences. "With Ashion, we've added a talented team, a CLIA-certified and CAP-accredited lab, deep sequencing capabilities, and one of the most comprehensive genomic cancer tests available on the market today with GEM ExTra®. This expertise will be integral in helping us extend our leadership in precision oncology and in serving more patients across the cancer continuum, including therapy selection and minimal residual disease testing."